Market Overview

UPDATE: Pareto Securities Downgrades AstraZeneca to Sell

Related AZN
Cardiovascular Players Could Be Eyeing Esperion
Anthrax And Government Contracts: PharmAthene And Altimmune Ahead Of Merger
CEO Gassner Makes Sure Veeva Has A 'Second Act' — And More (Investor's Business Daily)

Pareto Securities reduced its rating on AstraZeneca (NYSE: AZN) from Hold to Sell and lowered its price target from $48 to $44.

Pareto Securities noted, "AstraZeneca (AZN) did not surprise on revenues although margins overall were stronger than consensus expectations. The appointment of a new CEO and recent deals have lifted the valuation to new highs. We do not believe this is sustainable in the short term as 2013E numbers are not strong enough."

AstraZeneca closed at $46.70 on Thursday.

Latest Ratings for AZN

Dec 2016Leerink SwannUpgradesMarket PerformOutperform
Sep 2016PiperJaffrayInitiates Coverage onOverweight
Sep 2016Exane BNP ParibasDowngradesOutperformNeutral

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: Pareto SecuritiesAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings


Related Articles (AZN)

View Comments and Join the Discussion!